International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): International normalized ratio (INR) =< 3 (to be done/tested only for subjects on warfarin)
Patients receiving anticoagulation treatment are allowed to participate with international normalized ratio (INR) established within the therapeutic range
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
Obtained within 14 days prior to treatment start: International normalized ratio (INR) =< 1.5
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5
International normalized ratio (INR) < 1.1 x institutional upper limit of normal
International normalized ratio (INR) =< 1.2 X upper limit of normal (ULN)
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.2
International normalized ratio of < 1.5
International normalized ratio (INR)/PTT =< 2 times normal; timeline: within 3 weeks prior to enrollment
Blood coagulation parameters: international normalized ration (INR) =< 1.5
International normalized ratio (INR) ? 1.5 × ULN (? 2.5 × ULN if on anticoagulants)
International normalized ratio (INR) =< 1.5
Adequate coagulation tests: international normalized ratio ?1.5
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5
International normalized ratio (INR) = 1.7
International normalized ratio (INR) =< 1.5 unless on direct thrombin inhibitor at time of study entry
International normalized ratio (INR) =< 2
Coagulation: International normalized ratio (INR) ?1.2 within 28 days of starting study.
International normalized ratio (INR) ?1.5;
Adequate blood coagulation function defined by International Normalized Ratio (INR) ?1.5 (except for participants on warfarin therapy where INR must be ?3.0 prior to randomization)
International normalized ratio (INR) =< 1.5
Obtained =< 2 weeks prior to registration: International normalized ratio (INR) =< 1.5 ULN
International normalized ratio =< 1.5
International normalized ratio (INR) =< 1.5
International Normalized Ratio (INR) for coagulation above upper normal range
International normalized ratio (INR) ? 2 × ULN
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
International Normalized Ratio (INR) < 1.5 (except if patient is on oral anticoagulation therapy).
Must have an international normalized ratio (INR) < 1.5
International normalized ratio (INR) =< 1.5
International Normalized Ratio (INR) > 1.5
Normal coagulation defined as normal International Normalized Ratio (INR) or per institutional guidelines.
International normalized ratio (INR) < 1.5.
International normalized ratio (INR) =< 1.7
International normalized ratio (INR) < 2.0.
International normalized ratio (INR) less than 1. 5 X ULN
International normalized ratio (INR) < 1.5.
International normalized ratio (INR) < 1.3
International normalized ratio (INR) < 1.3
International normalized ratio > 1.5
Patients who have an international normalized ratio (INR) or platelet count which are not correctable to < 1.8 and > 35,000 respectively
Obtained with 21 days of registration: international normalized ratio =< 2.3
International normalized ratio (INR) =< 1.5 X institutional upper limit of normal (ULN) for patients not receiving therapeutic anticoagulation (unless dysfunction is secondary to lymphoma involvement)
International normalized ratio (INR) from 0.8 to 1.2
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ?1.5
International normalized ratio (INR) =< 1.5 (except for patients who are on full-dose warfarin)
International normalized ratio (INR) < 1.5
(For both cohorts A and B): International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 1.5 obtained < 4 weeks prior to starting treatment
International normalized ratio (INR) =< 1.5
International Normalized Ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5
International normalized ration (INR) within 1.25 x ULN institutional limits, except where a lupus anti-coagulant has been confirmed
International normalized ratio (INR) =< 1.7
Obtained within 14 days prior to registration; international normalized ratio (INR) ? 2
Completed within 60 days of surgery: International normalized ratio INR ? 1.5 in patients not utilizing systemic anticoagulation as part of their medical regimen
International normalized ratio (INR) =< 2.0 or correctable to 2.0 with vitamin K therapy
International normalized ratio (INR) > 1.5 INR
International normalized ratio (INR) =< 1.2
International normalized ratio (INR) < 1.5 x ULN
International normalized ratio (INR) >= 1.7
Obtained =< 14 days prior to registration: International normalized ratio (INR) =< 2.0
International normalized ratio (INR) < 1.5
International normalized ratio (INR) < 1.5
International normalized ratio (INR) =< 2
Therapeutic anticoagulation with international normalized ratio (INR) modifying drug of or use of antiplatelet therapy (with the exception of low dose aspirin < 325mg/d)
International normalized ratio (INR) =< 1.5 unless on warfarin in which case INR < 3.0 is acceptable
International normalized ration (INR) =< 1.5
The patient must have adequate coagulation function as defined by international normalized ratio (INR) =< 1.5 and
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 2.0
International normalized ratio (INR) =< 1.5 x institutional ULN
International normalized ratio (INR) is =< 1.5
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 2
International normalized ratio (INR) from 0.8 to 1.2
Coagulopathy international normalized ratio (INR) > 1.5
Known, existing uncontrolled coagulopathy, international normalized ratio (INR) > 1.5
International normalized ratio (INR) =< 1.5
Known coagulopathy/thrombocytopenia (international normalized ratio [INR] > 1.5, platelets < 75)
International normalized ratio (INR) < 2.0
International normalized ratio or INR must be =< 1.5 unless on therapeutic blood thinners
International normalized ratio (INR) < 1.3
“International normalized ratio” or INR must be =< 1.5
International normalized ratio (INR) =< 1.8
International normalized ratio (INR) =< 2
International normalized ratio (INR) < 1.3 x ULN
International normalized ratio (INR) value greater than 1.5
International normalized ratio (INR) =< 2
International normalized ratio (INR) < 2.0
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) < 2
International normalized ratio or INR must be =< 1.5 unless on therapeutic blood thinners
International normalized ratio (INR) < 2; subjects on anticoagulant (such as coumadin) must have an international normalized ratio (INR) < 5
International normalized ratio (INR) < 2.0
International normalized ratio (INR) must be =< 2.3
International normalized ratio (INR) =< 1.7
International normalized ratio (INR) < 1.3 (or < 3 if on warfarin or other anticoagulants) during screening evaluation
International normalized ratio (INR) > 2.0
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)
International normalized ration (INR) < 1.5
International normalized ratio (INR) ? 2 (If coagulopathy is related to disease, this criterion does not apply) within 14 days prior to registration
International normalized ratio (INR) =< 1.5 =< 14 days prior to registration
International normalized ratio or INR must be ? 1.5 unless on therapeutic blood thinners ? 2 weeks
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.4
Within 14 days prior to registration: International normalized ratio (INR) < 2.0
Performed within 14 days prior to study: International normalized ratio (INR) < 2 if off of anticoagulation; patients on anticoagulation therapy with an INR > 2 may be enrolled at the discretion of the investigator if they have not had any episodes of severe hemorrhage
International normalized ratio (INR) =< 1.5
ARM A: obtained =< 14 days prior to registration: \r\n* International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.4 unless receiving therapeutic doses of coumadin
International normalized ratio (INR) =< 2
International normalization ratio (INR) =< 2.0 mg/dL
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) < 1.3 (or < 3 if on warfarin or other anticoagulants)
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
Within 14 days of subject registration: International normalized ratio (INR) =< 1.5
International normalized ratio =< 1.3 (or =< 3 on anticoagulants)
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.2
International normalized ratio (INR) =< 1.5 X ULN (if not on anticoagulation)
International normalized ratio (INR) < 1.5 (or < 3 if on warfarin or other anticoagulants)
International normalized ratio (INR) =< 1.5
International normalized ratio or INR must be < 1.5
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 1.5 x institutional ULN
International normalized ratio (INR) =< 2.0
Inadequate liver or renal function; Intracranial bleeds or invasive malignancy over the previous 2 years - international normalized ratio (INR) laboratory values cannot be > 1.5 x upper limit of normal at study entry.
International normalized ratio (INR) =< 1.5
Performed within 14 days of patient registration: International normalized ration (INR) =< 1.5
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ? 1.5.
Coagulation: International Normalized Ratio (INR) ? 1.2
International normalized ratio (INR) =< 2, obtained =< 21 days prior to registration
Coagulation: International Normalized Ratio (INR) ? 1.2
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5.
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) > 2
International normalized ratio (INR) > 1.5
International normalized ratio (INR) within normal limits (UIHC)
Adequate blood coagulation function, defined as international normalized ratio (INR) less than or equal to 2.3
International normalized ratio (INR) < 1.5 x institutional ULN
International normalized ratio (INR) must be < 1.5
International normalized ratio (INR) =< 1.4 x ULN
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 2; factor 10A drawn if patient on anticoagulant Eliquis
International normalized ratio (INR) > 2 in the absence of anticoagulation therapy
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5.
International normalized ratio (INR) > 2
International normalized ratio (INR) =< 1.5
International normalized ratio > 1.7
International normalized ratio (INR) < 1.5 times ULN
International normalized ratio (INR) < 2.0
International normalized ratio (INR) < 1.5 x ULN for institution unless patient is on planned therapy with anticoagulants (i.e., warfarin) with higher target planned obtained =< 14 days prior to registration; in those cases, INR up to 3.5 is acceptable
International normalized ratio (INR) =< 1.5
international normalized ratio (INR) must be within normal limits of the local laboratory ranges.
International normalized ratio (INR) =< 2
International normalized ratio (INR) < 2
International normalized ratio (INR) =< 2
International normalized ratio (INR) less than or equal to 2
Adequate blood clotting time with an international normalized ratio (INR) < 2
International normalized ratio (INR) =< 2.0
International normalized ratio (INR) > 2
International Normalized Ratio (INR) less than 1.5 within 8 weeks prior to initial cryoablation procedure.
International normalized ratio (INR) must be less than 1.5 in patients not on Coumadin therapy
Patients receiving anticoagulation treatment are allowed to participate with international normalized ratio (INR) established within the therapeutic range
International normalized ratio (INR) < 1.3 (or < 3 on anticoagulants)
International normalized ratio (INR) must be =< 1.5 unless on therapeutic blood thinners
International normalized ratio (INR) =< 2.0 (unless due to therapeutic warfarin use)
International normalized ratio or INR must be =< 1.5 unless on therapeutic blood thinners
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) < 1.5 x ULN
International normalized ratio (INR) =< 2.5
Obtained within 2 weeks from study entry: International normalized ratio (INR) =< 2
International normalized ratio (INR) >= 1.5
International normalized ratio (INR) =< 1.5 unless using warfarin for therapeutic anti-coagulation
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.4
International normalized ratio (INR) > 1.5; (in patients receiving anticoagulants [such as warfarin] INR must be between 2.0 and 3.0 in two consecutive measurements 1-4 days apart)
Elevated international normalized ratio (INR) (> 1.7)
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5 (anticoagulation is allowed if target INR =< 1.5 on a stable dose for > 2 weeks at time of study entry)
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 1.7 (if not due to anticoagulants)
International normalized ratio (INR) =< 1.4 x ULN at the time of registration
Platelet count <50,000/mm3 or international normalized ratio >1.5.
International Normalized Ratio of at least 1.7 Adequate hepatic function including:
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 2
International normalized ratio (INR) ? 1.5 x ULN
International normalized ratio (INR) ? 1.5 x ULN
International normalized ratio (INR) < 1.5
“International normalized ratio” or INR must be =< 1.5
Ongoing treatment with warfarin unless the international normalized ratio (INR) is well controlled and below 4
International normalized ratio (INR) =< 1.5
For patients not receiving anticoagulation: international normalized ratio of a measure of prothrombin time (international normalized ratio [INR]) =< 1.3
International Normalized Ratio (INR) < 1.5 and aPTT within 1.1 x ULN
International normalized ratio (INR) < 1.5
International normalized ratio (INR) >1.5x ULN
International normalized ratio (INR) greater than 1.3
International Normalized Ratio (INR) ?1.7
Vitamin K antagonist therapy and an international normalized ratio >1.3 on the day of surgery.
An abnormal INR (international normalized ratio of greater than 1.3), if repeatable and refractory to correction by routine methods
International normalized ratio (INR) >= 1.5
Coagulation: International Normalized Ratio (INR) ? 1.2
International normalized ratio (INR) </=1.5 times ULN
International normalized ratio (INR) < 1.5 or patient off Coumadin at the time of ablation
International normalized ratio (INR) < 1.5; if on anticoagulation: INR is required to be between 2 and 3
Known coagulopathy (international normalized ratio [INR] > 1.5, platelets < 75 K)
International normalized ratio (INR) < 1.5 × ULN
International normalized ratio (INR) > 2.5 and/or
International normalized ratio (INR) less than or equal to (?) 1.6 (unless receiving anticoagulation therapy)
International normalized ratio (INR) =< 2
International normalized ratio (INR) < 1.3 (or ? 3.0 if on therapeutic anticoagulation)
International normalized ratio (INR) < 1.3 (or < 3 on anticoagulants)
International normalized ratio (INR) =< 1.5 x ULN; patients receiving anti-coagulation therapy are permitted as long as they have a stable INR =< 3.0
International normalized ratio (INR) =< 1.5 or
International normalized ratio (INR) =< 1.2 X upper limit of normal (ULN)
International normalized ratio (INR) =< 1.3 (or =< 3 on anticoagulants)
International normalized ratio (INR) < 1.5
International normalized ratio (INR) =< 2.0
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) > 2
Within 30 days of surgery: International normalized ratio (INR) =< 1.5
Patients with history of severe liver disease, defined as and confirmed by international normalized ratio (INR) 1.5 or greater per institutional laboratory.
International normalized ratio (INR) < 1.3 (or < 3 if on anticoagulant therapy).
International normalized ratio (INR) =< 1.5 (corrected if needed)
Currently on warfarin with an international normalized ratio (INR) > 1.4 or clopidogrel that cannot be discontinued 7 days prior to surgery
International normalized ratio (INR) > 1.5
International normalized ratio (INR) =< 1.8 times institutional upper limit of normal
Abnormal coagulation parameters (international normalized ratio [INR] > 1.5 not on Coumadin, or platelet count < 100,000)
Coagulopathy (international normalized ratio [INR] > 2, platelets < 50,000)
Obtained =< 30 days prior to randomization: International normalized ratio (INR) =< 1.6 (if not taking anticoagulant therapy)
International normalized ratio (INR) =< 1.5
Patients with international normalized ratio (INR) > 1.5
International normalized ratio (INR) =< 2
Minocycline trial only: patients who are under treatment of warfarin with international normalized ratio (INR) > 1.5
INR (International Normalized Ratio) <1.5 within 6 weeks screening
International normalized ratio (INR) =< 1.5 (within 30 days of surgery)
International normalized ratio (INR) =< 1.5
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 2
International normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) =< 1.3
International normalized ratio (INR) < 1.5 \r\n* For patients on Coumadin general clinical guidelines for interventional radiology (IR) ablation will be followed
Coagulopathy with international normalized ratio (INR) > 2.0 or
Severe coagulopathy (international normalized ratio [INR] > 1.8) or
Adequate blood coagulation as evidenced by an International Normalized Ratio (INR) ?1.5.
Low-density lipoprotein (LDL) question for lung surgery do we need an international normalized ratio (INR) < 1.6
International normalized ratio (INR) < 1.3 (or < 3 if on warfarin or other anticoagulants) at the screening visit
International Normalized Ratio (INR) < 1.5 (except if patient is on oral anticoagulation therapy).
International Normalized Ratio (INR) >1.5 x ULN
Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ?1.5.
